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Opportunity and Significance
Metabolic disorders affect many people and identifying
significantly perturbed biological processes in a
metabolic disease can provide valuable insight into the
disease’s mechanisms.
Evaluating the proposed Metabolic Pathway Analysis
Method (RAMP) will enable us to reliably use it to
identify significantly perturbed metabolic pathways that
could help identify disease mechanisms and potential
therapy targets or disease bio-markers of a metabolic
disorder.
Technical Approach
1. We applied a permutation approach to evaluate the rate of false
positives for the RAMP metabolic pathway analysis method.
2. We retrieved and processed publicly available metabolite data from
the Human Metabolome Database (HMDB)1 and parsed the data for
biological pathways from the Small Molecule Pathway Database
(SMPDB)2. The metabolite data and pathway information were linked
through metabolite identifiers from the Chemical Entities of Biological
Interest (ChEBI)3 database.
Next Steps for Development and Test
We will evaluate the method using simulated
pathways and data where the perturbed pathway is
known beforehand. Measures such as specificity and
sensitivity will be employed to evaluate the method’s
performance.
We will compare the RAMP analysis method with the
pathway analysis method implemented in the tool
MetaboAnalyst4 on the diabetes dataset and on other
disease datasets.
Technical Objectives
Design an evaluation procedure for the rate of false
positives of the RAMP analysis method.
Design an evaluation procedure for RAMP in the
context of diabetes metabolic data.
Related Work and State of Practice
Existing methods identify a list of metabolites, which
may be the effect of the disease rather than the cause.
Current methods do not take into consideration the
stoichiometry of the bio-chemical reaction or the
propagation of the metabolite changes from one
reaction to another.
The current project proposes to evaluate a method
which considers the stoichiometry and propagates the
change using an impact analysis approach.
Commercialization Plan & Partners
We will make RAMP and the evaluation available
in a software package.
Pitch it to bioinformatics start-ups to include it in
their software tools.
We will work with the resources available at WSU.
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Results
We used HMDB metabolite data for patients with diabetes and control
(healthy) patients. When compared to the classical enrichment
approach (hypergeometric test) RAMP returned fewer and more
relevant pathways (top 5 shown in Table 1).
For a sample pathway with 3
reactions (7 metabolites) and a
dataset generated from the
standard normal distribution. The
distribution of the p-values is
uniform which means that the rate
of false positives for a threshold of
α there would be no more than α
false positives in the results. Fig. 1. 1000 p-values computed for the
synthetic pathway. The null distribution was
built using 2000 permutations.
Table 1. Comparison of top 5 pathways ranked by p-value. Significant p-values are in bold (<1%)
RAMP Hypergeometric test
Pathway p-value FDR Pathway p-value FDR
1 Ketone Body Metabolism 0.00199 0.1774 Urate Degradation to Glyoxylate 0.09090 1
2 Succinyl CoA: 3-ketoacid
transferase deficiency
0.00249 0.1774 Urate Degradation to Ureidoglycolate 0.09090 1
3 Acetate metabolism 0.02348 0.7474 biotin-carboxyl carrier protein 
assembly
1 1
4 Butyrate Metabolism 0.03098 0.7474 2-ketoglutarate dehydrogenase 
complex deficiency
1 1
5 Isobutyryl-coa dehydrogenase 
deficiency
0.12943 0.7474 2-Methyl-3-Hydroxybutryl CoA
Dehydrogenase Deficiency
1 1
